Current and future treatments in multiple system atrophy.

Multiple system atrophy (MSA) is an atypical parkinsonian disorder characterized clinically by the development of parkinsonism, autonomic dysfunction, corticospinal degeneration, and cerebellar abnormalities. The cause of MSA is unknown, and progression is usually faster than idiopathic Parkinson's disease. No treatment is currently available to prevent or slow the progression of this neurodegenerative disorder. Available treatments are primarily symptomatic. This article reviews the current treatment options available for MSA in addition to emerging therapies in neuroprotection and neurotransplantation. Research into the neuropathology of MSA is being conducted and could lead to new more effective treatments within the next decade. The management for this disorder currently includes symptomatic and palliative strategies, as well as family education and support; the ultimate goal is to improve the quality of life for patients and their caregivers.